To be effective as of 1st May this year, Lispro will then be the lowest list-priced mealtime insulin available – less than the price of a Humalog vial back in 1999. On which point, Lilly is also ...

Eli Lilly and Company has a fifty-two week low ... Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin ...

Eli Lilly has responded to criticism of high prices for insulin products in the US by launching a cut-price version of its Humalog brand. The ‘authorised generic’ uses the same insulin lispro ...

Eli Lilly and Company discovers ... Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

In collaboration with Eli Lilly and Company (NYSE:LLY), a pharmaceutical company recognized globally for its innovative ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Eli Lilly is counting on Camurus and its long-acting delivery technology to help take its portfolio of obesity and diabetes drugs to the next level with a licensing deal worth up to $870 million.

Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have received a consensus rating of “Moderate Buy” from the twenty-one analysts that are covering the firm, Marketbeat.com reports.

In November 2023, U.S. and UK regulators approved Eli Lilly's rival weight-loss treatment Zepbound, after the company's diabetes drug was launched in 2022. In December 2024, Novo Nordisk's next ...